#USA #New Orleans #Nanoscope Therapeutics #optogenetic therapy #MCO-010

Nanoscope Therapeutics at ASGCT 2025

Nanoscope Therapeutics Inc., a pioneering biotech firm, is poised to make significant strides in vision restoration for blind patients during the upcoming American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting. This event will take place from May 13 to 17, 2025, at the Ernest N. Morial Convention Center in New Orleans. The company's focus on developing advanced optogenetic therapy platforms aims to address the needs of patients suffering from retinal degenerative diseases.

Headlining their presentations is the MCO-010 optogenetic therapy, which is notable for being mutation-agnostic and has demonstrated the potential to restore vision in advanced retinitis pigmentosa (RP) patients through a simple, one-time intravitreal injection. This innovative platform stands out as it is the most advanced therapy within Nanoscope's multi-characteristic opsin (MCO) portfolio, setting a new standard in gene therapy for retinal conditions.

Dr. Samarendra Mohanty, one of the co-founders and the President of Nanoscope Therapeutics, expressed enthusiasm for the upcoming presentations, emphasizing the efficacy and safety outcomes observed in various clinical trials. Notably, the results from trials involving Stargardt macular degeneration and geographic atrophy in non-human primate models will be presented to highlight the robust therapeutic benefits of MCO-010.

The comprehensive agenda includes both podium and poster presentations throughout the event. Key presentations on May 13 will feature Dr. Samarendra Mohanty discussing the efficacy of the MCO therapy in improving vision for models of geographic atrophy. Dr. Subrata Batabyal will also take the stage to share advancements in orthogonal potency assays that assess gene expression and light-stimulated activity of the MCO therapy.

Additionally, posters will showcase innovative studies on the delivery of bioengineered proteins sensitive to light for Stargardt patients, along with crucial data regarding the forced degradation of MCO therapy products. The discussions will provide insights into the advancements made by Nanoscope in accelerating regulatory approvals in cell and gene therapy.

Nanoscope Therapeutics' commitment to providing life-altering solutions for individuals suffering from retinal diseases is further underscored by their recent achievements, including successful Phase 2 clinical trials. The company plans to submit a Biologics License Application (BLA) for MCO-010 in 2025 based on the favorable study results. Driven by the need for effective treatments, Nanoscope aims to continue its pursuit of innovating therapies, with future trials planned for Stargardt patients as well.

As these groundbreaking developments unfold, the team at Nanoscope will be available for meetings during the conference, providing an opportunity for attendees to engage directly with the minds behind these potentially life-changing therapies. With ongoing research and dedicated efforts, Nanoscope Therapeutics stands at the forefront of a new era in vision restoration technology, paving the way for accessible treatments for millions of patients diagnosed with retinal degenerative diseases.

Through these presentations and collaborative discussions at the ASGCT 2025 Annual Meeting, Nanoscope Therapeutics aims to solidify its position as a leader in innovative biomedical solutions, reaffirming its commitment to restoring sight and enhancing the quality of life for those affected by blind-inducing conditions.